[go: up one dir, main page]

WO2019230957A1 - Composition pour accélérer la réparation musculaire - Google Patents

Composition pour accélérer la réparation musculaire Download PDF

Info

Publication number
WO2019230957A1
WO2019230957A1 PCT/JP2019/021752 JP2019021752W WO2019230957A1 WO 2019230957 A1 WO2019230957 A1 WO 2019230957A1 JP 2019021752 W JP2019021752 W JP 2019021752W WO 2019230957 A1 WO2019230957 A1 WO 2019230957A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
lactic acid
composition
cells
muscle repair
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2019/021752
Other languages
English (en)
Japanese (ja)
Inventor
忠昭 宮崎
久子 中川
敬弘 關
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Megmilk Snow Brand Co Ltd
Original Assignee
Megmilk Snow Brand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Megmilk Snow Brand Co Ltd filed Critical Megmilk Snow Brand Co Ltd
Priority to JP2020522633A priority Critical patent/JP7488182B2/ja
Publication of WO2019230957A1 publication Critical patent/WO2019230957A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Definitions

  • the present invention relates to a composition for promoting muscle repair.
  • Skeletal muscle is the largest organ that occupies about 40% of human body weight, and its functions range from general body movement to posture maintenance, energy metabolism, and protection of internal organs.
  • Skeletal muscle has a repair function. When physical or chemical damage occurs, muscle satellite cells located around muscle fibers work to repair the damaged site. Muscle satellite cells are normally stationary, but are activated when skeletal muscle is damaged and differentiate into myoblasts. After the myoblasts proliferate, they differentiate into myotubes and fuse to the damaged site to repair skeletal muscle.
  • Granulocyte colony-stimulating factor (Patent Document 1), ⁇ -hydroxy- ⁇ -methylbutyrate (Patent Document 2), and retinoic acid receptor ⁇ (RAR ⁇ ) agonist (Patent Document 3) are compounds that promote skeletal muscle repair. It has been reported.
  • Lactic acid bacteria are bacteria that produce lactic acid in the process of metabolism and have been used for various fermented foods since ancient times. In recent years, the functionality of lactic acid bacteria has attracted attention as probiotics (providing beneficial effects to the host by reaching the intestines alive).
  • An object of the present invention is to provide a novel composition for promoting muscle repair containing lactic acid bacteria as an active ingredient.
  • the present inventors have intensively studied. As a result, they found a lactic acid bacterium having a muscle repair promoting action and completed the present invention. That is, the present invention provides a novel composition for promoting muscle repair containing lactic acid bacteria as an active ingredient. Moreover, this invention provides the novel lactic acid strain which can be utilized industrially. Accordingly, the present invention has the following configuration. (1) A composition for promoting muscle repair, comprising as an active ingredient a bacterial cell belonging to Lactobacillus and / or a culture thereof.
  • Lactobacillus (Lactobacillus), Lactobacillus gasseri (Lactobacillus gastros), Lactobacillus delbacillus (Lactobacillus gasseri)
  • Lactobacillus belonging to Lactobacillus is Lactobacillus gasseri SBT2055 (FERM BP-10953), Lactobacillus delbruxi subspices delbrucky SBT0413 (NITE P-02642), Lactobacillus reuteri SBT02-STE26 PBT
  • Novel lactic acid bacterium Lactobacillus delbruecki subspecies delbruecki SBT0413 Novel lactic acid bacterium Lactobacillus delbruecki subspecies delbruecki SBT0413.
  • New lactic acid bacterium Lactobacillus reuteri SBT1926 Novel lactic acid bacterium Lactobacillus helveticus SBT11380.
  • composition for promoting muscle repair which comprises a bacterial cell belonging to Lactobacillus and / or a culture thereof as an active ingredient.
  • novel lactic acid strain which can be utilized industrially can be provided.
  • Lactobacillus Any lactic acid bacteria belonging to the genus Lactobacillus can be used as long as they belong to the genus Lactobacillus. Specific examples include Lactobacillus gasseri, Lactobacillus delbrucky sub-species delbrucky, etc. It is not limited to these.
  • the lactic acid bacteria belonging to the genus Lactobacillus of the present invention are Lactobacillus belonging to Lactobacillus, Lactobacillus gasseri SBT2055 (FERM BP-10953), Lactobacillus delbrucky Subspecies delbrucky SBT0402 (NTE P0402) Lactobacillus reuteri SBT1926 (NITE P-02643) and Lactobacillus helveticus SBT11380 (NITE P-02644).
  • Lactic acid bacteria belonging to the genus Lactobacillus may be cultured according to a conventional method for lactic acid bacteria culture to prepare a desired amount.
  • Lactic acid bacteria belonging to the genus Lactobacillus are cultured using an MRS (DIFCO) medium, and the resulting culture is collected by centrifugation to obtain bacterial cells.
  • the obtained microbial cells may be used as they are, or microbial cells subjected to concentration, drying, and lyophilization treatment may be used. Cells that have been killed by heat drying or the like can also be used.
  • Insoluble fraction of lactic acid bacteria belonging to the genus Lactobacillus (sediment) One embodiment of the method for preparing an insoluble fraction (sediment) of lactic acid bacteria belonging to the genus Lactobacillus of the present invention is shown below.
  • the lyophilized powder of Lactobacillus cells is suspended in a buffer and heated at 80 ° C. for about 30 minutes to obtain heated cells.
  • the heated cells are crushed with a French press.
  • the disrupted solution is centrifuged to remove the supernatant to obtain a sediment of lactic acid bacteria belonging to the genus Lactobacillus.
  • the active ingredient can be an insoluble fraction of crushed cells, and more specifically, an insoluble fraction of the crushed cells in a buffer solution (for example, phosphate buffer). Can be minutes.
  • a soluble fraction of the microbial cell disruption product may or may not be included additionally.
  • Lactobacillus strains include Lactobacillus delbruecki subspices delbruecki (Lactobacillus delbrueckii subsp. Delbrueckii) SBT0413 (NITE P-02642), Lactobacillus reuteri (Lactobils Reuteri Lactobacillus helveticus SBT11380 (NITE P-02644).
  • the lactic acid strain may be referred to as “the lactic acid bacterium of the present invention”, “the lactic acid strain of the present invention”, or simply SBT0413, SBT1926, and SBT11380.
  • lactic acid strains were transferred to SBT0413 in the Patent Evaluation Microorganism Depositary Center of the National Institute of Technology and Evaluation (Postal 292-0818, 2-5-8 122, Kazusa-Kamashita, Kisarazu City, Chiba Prefecture).
  • NITE P-02642, SBT1926 is deposited with NITE P-02643, and SBT11380 is deposited with NITE P-02644.
  • the lactic acid bacteria of the present invention are not limited to the above lactic acid strains, and may be lactic acid strains substantially equivalent to these deposited lactic acid strains.
  • Substantially equivalent lactic acid strains are lactic acid strains belonging to Lactobacillus delbruecki subspecies delbrucky, Lactobacillus reuteri, Lactobacillus helveticus, and have the same level of muscle repair promoting activity as deposited lactic acid strains Say.
  • the substantially equivalent lactic acid strain further has a base sequence of the 16S rRNA gene of 98% or more, preferably 99% or more, more preferably 100% of the base sequence of the 16S rRNA gene of the deposited lactic acid strain. It has homology and preferably has the same mycological properties as the deposited lactic acid strain.
  • the lactic acid bacteria of the present invention were bred from the deposited lactic acid strain or a substantially equivalent lactic acid strain by mutation treatment, genetic recombination, selection of natural mutant strains, etc., as long as the effects of the present invention were not impaired. It may be a lactic acid strain.
  • the composition of the present invention can also contain microbial cells subjected to concentration, drying, freeze-drying treatment, dead microbial cells obtained by heat drying, etc., it can be used as an active ingredient. Can be widely used.
  • the administration target of the composition of the present invention is not particularly limited and can be administered to a human, but the administration target may be an animal other than a human (for example, a dog, a cat, a horse or a rabbit).
  • the administration subject is a human, it can be administered to a minor, an adult, an elderly person 65 years or older, or the like under 20 years old.
  • the intake of the composition of the present invention is individually determined in consideration of the symptoms, age, etc. of the subject of administration, but it is usually 0.5-5000 mg for an adult, 0.5-500 mg 0.5-50 mg is most desirable. (Evaluation method of muscle repair promotion effect) Evaluation can be performed by the method described in Examples. That is, evaluation can be performed by the following method.
  • Lactobacillus gasseri SBT2055 heated cells are crushed three times at 1,200 psiG with a French press (Aminco). After crushing, centrifugation (4 ° C., 7000 rpm, 15 minutes) is performed to obtain a supernatant and a sediment. Furthermore, the supernatant was filtered through a 0.22 ⁇ m filter. For the sediment, add PBS (-) in an amount equal to the removed supernatant, vortex and then centrifuge (4 ° C, 7000 rpm, 15 minutes) to remove the supernatant. This is repeated three times, and a supernatant added with an equal volume of PBS ( ⁇ ) is used as the sediment.
  • the concentration of the crushed supernatant and sediment obtained from 10 mg / ml Lactobacillus gasseri SBT2055 heated cells subjected to a French press is set to an equivalent amount of 10 mg / ml, respectively.
  • C2C12 mouse myoblasts were seeded in collagen-coated 96-well plates at 5,000 cells / well, cultured at 37 ° C.
  • bupivacaine hydrochloride (Wako Pure Chemical Industries) was used. Let react for hours. Thereafter, bupivacaine is removed, and unbroken heated cells, crushed supernatant or crushed sediment is added, and myoblasts are cultured for 48 hours. After culturing, washing with sterile PBS ( ⁇ ) is performed twice, and then cell counting kit-8 (Dojindo Laboratories) is added and reacted at 37 ° C. for 2 hours, and the absorbance at 450 nm is measured.
  • the obtained absorbance value is applied to the formula of (heated cell-blank) / (heat cell not added-blank) ⁇ 100 to calculate the growth rate. If the growth promotion effect of myoblasts by lactic acid bacteria is increased compared to the case of non-heated cells added, it can be determined that the proliferation of myoblasts after injury was promoted.
  • Example product 1 Heated cells of lactic acid bacteria Each test bacterium of the following (1) was inoculated into MRS medium (DIFCO), and static culture was performed at 37 ° C for 16 hours. The culture was centrifuged (4 ° C., 7000 rpm, 15 minutes), and then washed with sterilized water and centrifuged three times to obtain washed cells. The washed cells were freeze-dried to obtain cell powder. The bacterial cell powder was diluted with sterile PBS ( ⁇ ) to 10 mg / ml and heated at 80 ° C. for 30 minutes to obtain heated bacterial cells.
  • MRS medium DIFCO
  • Lactobacillus gasseri (Lactobacillus gasseri) SBT2055 (FERM BP-10953), Lactobacillus del Burukki subsp. Bulgaricus (Lactobacillus delbrueckii subsp. Bulgaricus) SBT2115, Lactobacillus del Burukki subsp del Burukki (Lactobacillus delbrueckii subsp.
  • C2C12 mouse myoblasts were cultured in DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin-streptomycin (SIGMA).
  • C2C12 mouse myoblasts were seeded in collagen-coated 96-well plates at 5,000 cells / well, cultured at 37 ° C. for 24 hours in a 5% CO 2 incubator, and then 0.5 ⁇ M bupivacaine hydrochloride (Wako Pure Chemical Industries) was used. Reacted for hours. Thereafter, bupivacaine was removed, each heated cell was added, and myoblasts were cultured for 48 hours.
  • the cells were washed twice with sterile PBS ( ⁇ ), cell counting kit-8 (Dojindo Laboratories) was added, and the mixture was reacted at 37 ° C. for 2 hours, and the absorbance at 450 nm was measured. The obtained absorbance value was applied to the formula of (heated cell added-blank) / (heated cell non-added-blank) ⁇ 100 to calculate the growth rate. If the growth promotion effect of myoblasts by lactic acid bacteria is increased compared to the case of non-heated cells added, it can be determined that the proliferation of myoblasts after injury was promoted.
  • Example 2 Concentration-dependent effect of Lactobacillus gasseri SBT2055 heated cells (preparation of lactic acid bacteria) Regarding Example Product 1, the concentration-dependent muscle repair promoting effect of bacterial cells was examined.
  • SIGMA DMEM
  • FBS FBS
  • SIGMA penicillin-streptomycin
  • Lactobacillus gasseri SBT2055 myoblast proliferation rate for each heated cell concentration is shown in FIG.
  • an increase in the proliferation rate of myoblasts was observed depending on the concentration of Lactobacillus gasseri SBT2055 heated cells. Therefore, the concentration dependency of Lactobacillus gasseri SBT2055 heated cells was observed in the effect of promoting the proliferation of myoblasts after injury.
  • Example 3 Search for effective components of Lactobacillus gasseri SBT2055 heated cells (preparation of lactic acid bacteria) For Example Product 1, the effect of promoting the muscle repair of the soluble fraction (supernatant) and the insoluble fraction (sediment) of the crushed cells was examined.
  • Test method 10 mg / ml Lactobacillus gasseri SBT2055 heated cells were crushed three times at 1,200 psiG with a French press (Aminco). After crushing, centrifugation (4 ° C., 7000 rpm, 15 minutes) was performed to obtain a supernatant and a sediment. Furthermore, the supernatant was filtered through a 0.22 ⁇ m filter.
  • the precipitate was added with an equal amount of PBS (-) to the removed supernatant, vortexed and centrifuged (4 ° C, 7000 rpm, 15 minutes) to remove the supernatant. This was repeated 3 times, and a supernatant added with an equal amount of PBS ( ⁇ ) was used as the sediment.
  • Concentrations of the crushed supernatant and sediment obtained from 10 mg / ml Lactobacillus gasseri SBT2055 heated cells subjected to a French press were each equivalent to 10 mg / ml. Dilute with DMEM (SIGMA) containing 10% FBS (GIBCO) and 1% penicillin-streptomycin (SIGMA) to an amount equivalent to 100 ⁇ g / ml.
  • C2C12 mouse myoblasts were seeded in collagen-coated 96-well plates at 5,000 cells / well, cultured at 37 ° C. for 24 hours in a 5% CO 2 incubator, and then 0.5 ⁇ M bupivacaine hydrochloride (Wako Pure Chemical Industries) was used. Reacted for hours. Thereafter, bupivacaine was removed, and unbroken heated cells, crushed supernatant, or crushed sediment was added, and myoblasts were cultured for 48 hours. After culturing, the cells were washed twice with sterile PBS ( ⁇ ), cell counting kit-8 (Dojindo Laboratories) was added, and the mixture was reacted at 37 ° C.
  • sterile PBS ⁇
  • cell counting kit-8 Dojindo Laboratories
  • Example product 2 Preparation of lactic acid bacteria culture Lactobacillus gasseri SBT2055 was cultured in MRS liquid medium (DIFCO). Each culture solution in the logarithmic growth phase was inoculated with 1% in 10% reduced skim milk (115 ° C., sterilized for 20 minutes) supplemented with 0.3% yeast extract to prepare mother cultures. 10% reduced skim milk was added thereto, and 2.5% was added to the yogurt mix heated at 100 ° C. for 10 minutes. Fermentation was performed at 37 ° C., and when the lactic acid acidity reached 0.85, the mixture was cooled to terminate the fermentation. The obtained fermented milk was freeze-dried to obtain a powder of Lactobacillus gasseri SBT2055 cell culture. The obtained cell culture was resuspended in phosphate buffer and adjusted to 1 ⁇ 10 9 cells / ml.
  • DIFCO MRS liquid medium
  • Example product 3 Preparation of lactic acid bacterial cells Lactobacillus gasseri SBT2055 was inoculated into MRS liquid medium (DIFCO), and static culture was performed at 37 ° C for 16 hours. The culture was centrifuged at 4 ° C. and 7000 rpm for 15 minutes, and then washed with sterilized water and centrifuged three times to obtain washed cells. The washed cells were freeze-dried to obtain cell powder.
  • DIFCO MRS liquid medium
  • Example Product 4 Manufacture of Tablets 1 part of the bacterial cell powder prepared in Example Product 3 was mixed with 4 parts of skim milk powder, and this mixed powder was tableted 1 g by a conventional method using a tableting machine. Tablets containing 200 mg of cells of Lactobacillus gasseri SBT2055 of the invention were prepared.
  • Example product 5 Manufacture of powder After intake of Lactobacillus gasseri SBT2055 in 5 L of MRS liquid medium (DIFCO), static culture was performed at 37 ° C for 18 hours. After completion of the culture, centrifugation was performed at 7000 rpm for 15 minutes to obtain 1/50 amount of concentrated bacterial cells of the culture solution. Next, the concentrated cells were mixed with the same amount of a dispersion medium containing 10% by weight of skim milk powder and 1% by weight of sodium glutamate, adjusted to pH 7, and then freeze-dried. The obtained freeze-dried product was sized with a 60-mesh sieve to produce freeze-dried bacterial powder.
  • DIFCO MRS liquid medium
  • Example Product 6 Production of Capsule After mixing the raw materials according to the formulation shown in Table 1 and granulating by granulation, 10 mg each was filled into empty capsules to produce a capsule.
  • Example product 7 Production of stick-like health food To 30 g of the powder of Example product 1, 40 g of an equal mixture of vitamin C and citric acid, 100 g of granulated sugar, and 60 g of an equal mixture of corn starch and lactose were added and mixed. The mixture was packed in stick bags to produce stick health food.
  • Example product 8 Manufacture of beverages After mixing the raw materials according to the formulation shown in Table 2 and filling the containers, heat sterilization was performed to produce fruit juice beverages.
  • a muscle repair promoter comprising a lactic acid bacterial cell belonging to Lactobacillus and / or a lactic acid bacterial culture as an active ingredient.
  • Lactobacillus gasseri SBT2055 (I) Name and address of the depository institution that deposited the biological material, Patent Evaluation Facility, National Institute of Technology and Evaluation 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 120 (zip code 292-0818) Date of deposit of biological materials at the depository in Loi March 27, 1996 February 26, 2008 (the date of transfer to the deposit under the Budapest Treaty by the original deposit) Deposit number FERM BP-10953 assigned to the depositary by the high depository (2) Lactobacillus delbruecki subspecies delbruecki SBT0413 (I) Name and address of the depositary institution that deposited the biological material, Patent Evaluation Microorganism Deposit Center, National Institute of Technology and Evaluation 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 (zip code 292-0818) Date of deposit of biological materials at the depository in Loi February 21, 2018 Deposit number N
  • the receipt number is NITE ABP-02642.
  • Lactobacillus reuteri SBT1926 I) Name and address of the depositary institution that deposited the biological material, Patent Evaluation Microorganism Deposit Center, National Institute of Technology and Evaluation 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 (zip code 292-0818) Date of deposit of biological materials at the depository in Loi February 21, 2018 Deposit number NITE P-02643 attached to the deposit by the depository in Hai (deposited under the Budapest Treaty based on the original deposit after the original deposit date) (The application was transferred on May 27, 2019, and after completion of the survival confirmation test, we received a letter notifying the receipt number.
  • the receipt number is NITE ABP-02643.
  • Lactobacillus helveticus SBT11380 I) Name and address of the depositary institution that deposited the biological material, Patent Evaluation Microorganism Deposit Center, National Institute of Technology and Evaluation 2-5-8, Kazusa Kamashi, Kisarazu, Chiba, Japan Room 122 (zip code 292-0818) Date of deposit of biological materials at the depository in Loi February 21, 2018 Deposit number NITE P-02644 given by the depository in the high (deposited under the Budapest Treaty based on the original deposit after the original deposit date) (The application was transferred on May 27, 2019, and after completion of the survival confirmation test, we received a letter notifying the receipt number.
  • the receipt number is NITE ABP-02644.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention aborde le problème de l'obtention d'une nouvelle composition pour accélérer la réparation musculaire. Des cellules et/ou une culture d'une bactérie appartenant à Lactobacillus sont utilisée en tant que principe actif, permettant d'obtenir un aliment, une boisson ou un aliment efficace pour accélérer la réparation musculaire.
PCT/JP2019/021752 2018-06-01 2019-05-31 Composition pour accélérer la réparation musculaire Ceased WO2019230957A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020522633A JP7488182B2 (ja) 2018-06-01 2019-05-31 筋修復促進用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018105946 2018-06-01
JP2018-105946 2018-06-01

Publications (1)

Publication Number Publication Date
WO2019230957A1 true WO2019230957A1 (fr) 2019-12-05

Family

ID=68697591

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/021752 Ceased WO2019230957A1 (fr) 2018-06-01 2019-05-31 Composition pour accélérer la réparation musculaire

Country Status (2)

Country Link
JP (1) JP7488182B2 (fr)
WO (1) WO2019230957A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065330A1 (fr) 2020-09-23 2022-03-31 雪印メグミルク株式会社 Agent de prévention de l'atrophie musculaire
WO2023249423A1 (fr) * 2022-06-22 2023-12-28 (주)에이스바이옴 Composition comprenant lactobacillus gasseri pour prévenir et traiter la sarcopénie
JP7701090B1 (ja) * 2024-03-06 2025-07-01 株式会社未来生命科学研究院 経口組成物
KR102892032B1 (ko) 2023-11-28 2025-11-28 주식회사 쎌바이오텍 근감소증 예방 및 개선 기능성을 가지는 유산균주 락토바실러스 가세리 cbt lga2
JP7791828B2 (ja) 2020-09-23 2025-12-24 雪印メグミルク株式会社 筋委縮予防剤

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031749A1 (fr) * 2011-08-29 2013-03-07 株式会社明治 Bactéries lactiques permettant de favoriser l'activité physique
US20150335688A1 (en) * 2014-05-21 2015-11-26 Medlab Ip Pty Ltd Probiotic combinations and uses thereof
JP2016216408A (ja) * 2015-05-22 2016-12-22 アサヒグループホールディングス株式会社 筋肉の分解抑制剤
WO2018003900A1 (fr) * 2016-06-30 2018-01-04 アサヒグループホールディングス株式会社 Composition pour une utilisation dans l'amélioration de l'état nutritionnel
JP2018083761A (ja) * 2016-11-21 2018-05-31 アサヒグループホールディングス株式会社 筋肉の分解抑制剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031749A1 (fr) * 2011-08-29 2013-03-07 株式会社明治 Bactéries lactiques permettant de favoriser l'activité physique
US20150335688A1 (en) * 2014-05-21 2015-11-26 Medlab Ip Pty Ltd Probiotic combinations and uses thereof
JP2016216408A (ja) * 2015-05-22 2016-12-22 アサヒグループホールディングス株式会社 筋肉の分解抑制剤
WO2018003900A1 (fr) * 2016-06-30 2018-01-04 アサヒグループホールディングス株式会社 Composition pour une utilisation dans l'amélioration de l'état nutritionnel
JP2018083761A (ja) * 2016-11-21 2018-05-31 アサヒグループホールディングス株式会社 筋肉の分解抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MATSUO K. ET AL.: "Contribution of lactobacillus casei to the recovery from chemically induced skeletal muscle damage under chronic stress", INTERNATIONAL JOURNAL OF EXERCISE SCIENCE, September 2013 (2013-09-01) *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022065330A1 (fr) 2020-09-23 2022-03-31 雪印メグミルク株式会社 Agent de prévention de l'atrophie musculaire
JPWO2022065330A1 (fr) * 2020-09-23 2022-03-31
JP7791828B2 (ja) 2020-09-23 2025-12-24 雪印メグミルク株式会社 筋委縮予防剤
WO2023249423A1 (fr) * 2022-06-22 2023-12-28 (주)에이스바이옴 Composition comprenant lactobacillus gasseri pour prévenir et traiter la sarcopénie
KR102892032B1 (ko) 2023-11-28 2025-11-28 주식회사 쎌바이오텍 근감소증 예방 및 개선 기능성을 가지는 유산균주 락토바실러스 가세리 cbt lga2
JP7701090B1 (ja) * 2024-03-06 2025-07-01 株式会社未来生命科学研究院 経口組成物

Also Published As

Publication number Publication date
JP7488182B2 (ja) 2024-05-21
JPWO2019230957A1 (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
US10793925B2 (en) Lactobacillus paracasei for the production of conjugated linoleic acid, nutritional and pharmaceutical preparations containing it and uses thereof
EP4316270A1 (fr) Composition susceptible de faciliter la défécation et son utilisation
TWI572713B (zh) 抗肥胖之乳酸菌菌株及其於食品組成物以及醫藥組成物之應用
WO2019230957A1 (fr) Composition pour accélérer la réparation musculaire
JP7179343B2 (ja) 新規な乳酸菌株およびそれを含む免疫賦活剤
KR101426275B1 (ko) 지방합성 억제 및 지방산화 촉진에 의한 체지방 감소 효능을 갖는 5종의 유산균 복합균주를 유효성분으로 함유하는 조성물
JP7555439B2 (ja) 骨格筋遅筋化用組成物
JP6649539B1 (ja) 脂肪蓄積抑制用組成物
US20230330165A1 (en) Muscle atrophy prevention agent
TWI782550B (zh) 具減少脂肪與提升運動表現的乳酸菌組合物及其用途
CN117384790A (zh) 一株戊糖片球菌ks5及其在制备抗炎和助睡眠食品药品中的应用
JP7362081B2 (ja) 新規な乳酸菌株及びその用途
Kimoto-Nira et al. Growth characteristics of Lactobacillus brevis KB290 in the presence of bile
CN116445327A (zh) 一种降血脂多元益生菌及其应用
JP7090288B2 (ja) 新規乳酸菌、新規乳酸菌を有効成分として含有する自然免疫活性化剤、及び新規乳酸菌を含有する飲食品
JP2003252772A (ja) 加齢に伴う代謝異常症の予防・改善・治療剤
JP7606276B2 (ja) 脂質代謝改善用組成物
KR101809616B1 (ko) 항비만효과를 가지는 케피어 유래 프로바이오틱 균주
KR102323673B1 (ko) HtrA 샤페론 프로바이오틱스의 제조방법 및 이를 통해 제조된 장 마이크로바이옴 조절 효능이 있는 염증성 장질환 치료용 조성물
CN110079477B (zh) 一株防治鸡白痢沙门氏菌病的植物乳杆菌及其制剂和应用
JP7663240B2 (ja) 腸管免疫賦活剤及びＩｇＡ産生促進剤
JP6928195B1 (ja) 免疫鎮静作用を有する乳酸菌
JP7077458B1 (ja) 免疫賦活化作用を有する乳酸菌
JP2019071879A (ja) 乳酸醗酵ニンジンの製造方法
JP7331310B2 (ja) 免疫賦活活性を有する乳酸菌又はその処理物の保存時間経過による免疫賦活活性の低下を抑制するための組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19811427

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020522633

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19811427

Country of ref document: EP

Kind code of ref document: A1